Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nordic files patent infringement/false ads suit

This article was originally published in The Tan Sheet

Executive Summary

Watsonville, Calif.-based Nordic Naturals files suit May 4 in the U.S. District Court for the District of Northern California against Arlington Heights, Ill.-based J.R. Carlson Laboratories and San Clemente, Calif.-based Metagenics, alleging lemon-flavored fish oil capsules sold by both companies infringes on two of three method-of-manufacture patents covering its proprietary fruit flavored omega-3 and related softgel capsules. The suit also charges the companies with falsely marketing their products as flavored capsules. Nordic Founder and CEO Joar Opheim told "The Tan Sheet:" "We believe that there was sufficient basis to file suit. We feel that a line has been crossed so we took action to protect our legal rights." The parties are scheduled to meet at the court in August regarding the lawsuit, Opheim said. Carlson and Metagenics have not responded to the suit...

You may also be interested in...



Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.

Topics

UsernamePublicRestriction

Register

PS100549

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel